Taking everything into account, DRRX scores 2 out of 10 in our fundamental rating. DRRX was compared to 190 industry peers in the Pharmaceuticals industry. The financial health of DRRX is average, but there are quite some concerns on its profitability. DRRX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year DRRX has reported negative net income.
In the past year DRRX has reported a negative cash flow from operations.
DRRX had negative earnings in each of the past 5 years.
DRRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -27.86%, DRRX perfoms like the industry average, outperforming 54.31% of the companies in the same industry.
DRRX has a Return On Equity (-99.86%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-27.86%
ROE	-99.86%
ROIC	N/A

ROA(3y)-55.09%

ROA(5y)-41.09%

ROE(3y)-139.78%

ROE(5y)-96.71%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of DRRX (62.60%) is better than 70.56% of its industry peers.
In the last couple of years the Gross Margin of DRRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for DRRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	62.6%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.8%

GM growth 5Y0.25%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRRX has been increased compared to 1 year ago.
DRRX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DRRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

DRRX has an Altman-Z score of -67.96. This is a bad value and indicates that DRRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -67.96, DRRX is not doing good in the industry: 92.39% of the companies in the same industry are doing better.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-67.96

ROIC/WACCN/A

WACC10.88%

2.3 Liquidity

DRRX has a Current Ratio of 0.98. This is a bad value and indicates that DRRX is not financially healthy enough and could expect problems in meeting its short term obligations.
DRRX's Current ratio of 0.98 is on the low side compared to the rest of the industry. DRRX is outperformed by 80.71% of its industry peers.
DRRX has a Quick Ratio of 0.98. This is a bad value and indicates that DRRX is not financially healthy enough and could expect problems in meeting its short term obligations.
DRRX has a Quick ratio of 0.95. This is in the lower half of the industry: DRRX underperforms 74.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.98
Quick Ratio	0.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.61% over the past year.
Looking at the last year, DRRX shows a very negative growth in Revenue. The Revenue has decreased by -62.89% in the last year.
Measured over the past years, DRRX shows a very negative growth in Revenue. The Revenue has been decreasing by -39.51% on average per year.

EPS 1Y (TTM)83.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%41.67%

Revenue 1Y (TTM)-62.89%

Revenue growth 3Y-47.43%

Revenue growth 5Y-39.51%

Sales Q2Q%-79.41%

3.2 Future

Based on estimates for the next years, DRRX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.95% on average per year.
The Revenue is expected to grow by 53.91% on average over the next years. This is a very strong growth

EPS Next Y-105.89%

EPS Next 2Y-24.45%

EPS Next 3Y57.26%

EPS Next 5Y60.95%

Revenue Next Year-92.31%

Revenue Next 2Y-22.88%

Revenue Next 3Y45.1%

Revenue Next 5Y53.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DRRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.